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tDown syndrome confers a 20-fold increased risk of B cell acute lymphoblastic leukemia (B-
ALL)1 and polysomy 21 is the most frequent somatic aneuploidy amongst all B-ALLs2. Yet, the
mechanistic links between chr.21 triplication and B-ALL remain undefined. Here we show that
germline triplication of only 31 genes orthologous to human chr.21q22 confers murine progenitor
B cell self-renewal in vitro, maturation defects in vivo, and B-ALL with either BCR-ABL or
CRLF2 with activated JAK2. Chr.21q22 triplication suppresses H3K27me3 in progenitor B cells
and B-ALLs, and “bivalent” genes with both H3K27me3 and H3K4me3 at their promoters in
wild-type progenitor B cells are preferentially overexpressed in triplicated cells. Strikingly, human
B-ALLs with polysomy 21 are distinguished by their overexpression of genes marked with
H3K27me3 in multiple cell types. Finally, overexpression of HMGN1, a nucleosome remodeling
protein encoded on chr.21q223–5, suppresses H3K27me3 and promotes both B cell proliferation in
vitro and B-ALL in vivo.
To directly interrogate the effects of polysomy 21, we assayed B cell development in
Ts1Rhr mice (Fig. 1a), which harbor a triplication of 31 genes and one non-coding RNA on
mouse chr.16 orthologous to a segment of human chr.21q226. The triplicated genes also
overlap with a region of recurrent intrachromosomal amplification of chr.21q22 (iAMP21)
in human B-ALL 7. Bone marrow from 6-week-old Ts1Rhr mice had fewer total progenitor
(B220+CD43+) B and pro-B (Hardy B and C)8 cells than wild-type littermates, while the
pre-pro-B (Hardy A) fraction was unaffected (Fig. 1b, Supplementary Fig. 1a). C57BL/6
Ts1Rhr, FVBxC57BL/6 F1 Ts1Rhr and Ts65Dn mice9, which harbor a larger triplication
(Fig. 1a), all had similar reductions in pro-B cells (Supplementary Fig. 1b). This
differentiation defect essentially phenocopies human fetal livers with trisomy 21, which
have reduced pre-pro-B (CD34+CD19+CD10-) and pro-B cells (CD34+CD19+CD10+)10.
We performed competitive transplantation using equal mixtures of congenic CD45.1 wild-
type bone marrow and CD45.1/CD45.2 bone marrow from either Ts1Rhr or wild-type mice
(Supplementary Fig. 1c). After 16 weeks, recipients of wild-type CD45.1 and CD45.1/45.2
bone marrow had equal representations of both populations in Hardy A, B and C fractions as
well as whole bone marrow (Fig. 1c, Supplementary Fig. 1d). In contrast, mice that received
wild-type CD45.1 mixed with Ts1Rhr CD45.1/45.2 recapitulated the Ts1Rhr defect, with
significant reductions in CD45.1/45.2 Hardy B and C fractions (Fig.1c, Supplementary Fig.
1d). Thus, the differentiation effect is independent of non-hematopoietic cells.
To address whether chr.21q22 triplication directly confers transformed phenotypes in vitro,
we generated progenitor B cell colonies from unselected Ts1Rhr and wild-type bone marrow
in three-dimensional cultures with IL7 (Supplementary Figs. 1e–f). Wild-type bone marrow
forms colonies (termed ‘passage 1’) that replate to form new colonies for 1–2 additional
passages. In contrast, Ts1Rhr bone marrow generated more colonies in early passages and
serially replated indefinitely (Fig. 1d), which indicates self-renewal capacity. There were no
differences between Ts1Rhr and wild-type bone marrow in the number or repassaging
potential of myeloid colonies (Fig. 1e).
Sixty percent of Down syndrome-associated B-ALLs harbor CRLF2 rearrangements that
commonly co-occur with activating JAK2 mutations11–13. To model this, we generated Eµ-
CRLF2 (hereafter ‘C2’) and Eµ-JAK2 R683G (‘J2’) transgenic mice, which restricts
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ttransgene expression to B cells. C2/J2 and C2/J2/Pax5+/− mice did not develop B-ALL by
18 months of age (data not shown). Transduction of C2/J2/Pax5+/− bone marrow with
dominant-negative IKZF1 (Ik6)14 and transplantation into wild-type recipients resulted in
CRLF2-positive B-ALL in all mice by 120 days (Supplementary Fig. 2a–b). Control mice
lacking C2, J2 or Pax5 heterozygosity did not develop B-ALL with Ik6 (Supplementary Fig.
2b), establishing this transgenic combination as the first model of CRLF2/JAK2-driven B-
ALL. Mice transplanted with Ts1Rhr/C2/J2/Pax5+/− bone marrow transduced with a lower
titer of Ik6-encoding virus developed B-ALL with greater penetrance and reduced latency
compared to C2/J2/Pax5+/− alone (Fig. 1f). The same genotypes (C2/J2/Pax5+/−/Ik6 with or
without polysomy 21) occur in high-risk cases of human B-ALL15, supporting the validity
of the model.
Although BCR-ABL-rearranged ALL is uncommon in children with Down syndrome,
polysomy 21 is the most common somatic aneuploidy in these leukemias16. Ts1Rhr and
wild-type bone marrow had similar transduction efficiencies with p210 BCR-ABL17
(Supplementary Fig. 2c) but mice (C57BL/6 and FVBxC57BL/6 F1 backgrounds) that
received transduced Ts1Rhr bone marrow succumbed to B-ALL with shorter latency and
increased penetrance (Fig. 1g, Supplementary Fig. 2d–f). Transplantation of BCR-ABL-
transduced sorted Hardy B cells from Ts1Rhr or wild-type mice recapitulated the same
effect (Supplementary Fig. 2g), indicating that chr.21q22 triplication confers leukemogenic
effects that are progenitor B-cell autonomous.
Previous reports suggested that polysomy 21 contributes to leukemogenesis by promoting
aberrant DNA double-strand break repair (DSBR)18,19. To address this, we generated
otherwise isogenic retinal pigment epithelial (RPE) cells with 3 or 4 copies of human chr.21
(Supplementary Fig. 3a–c). Using targeted DSBR reporters20,21, polysomy 21 had no effect
on either homology-directed repair frequency or junction characteristics formed by
nonhomologous end-joining, whether DSBs were induced by the I-SceI meganuclease or by
the V(D)J recombinase (Supplementary Fig. 3d–j). Although a subtle defect or one specific
to B cells remains possible, these results indicate in an isogenic system that polysomy 21
does not drastically affect DSBR phenotype.
We next performed whole transcriptome sequencing (RNA-seq) of passage 1 B cells. As
expected, triplicated loci in Ts1Rhr cells were expressed at approximately 1.5-fold higher
levels compared to wild-type cells (Supplementary Fig. 4). We defined a transcriptional
“Ts1Rhr gene set” of the 150 most differentially expressed genes compared to wild-type
(Supplementary Table 1A–B). As expected, this signature was highly enriched by gene set
enrichment analysis (GSEA)22 for human chr.21q22 genes but not other human
chromosomal segments (Supplementary Table 1C)22. The Ts1Rhr B cell signature was
enriched among human Down syndrome-ALLs by GSEA (Fig. 2a–b; FDR=0.019) in a
dataset of pediatric B-ALLs (AIEOP)19. By hierarchical clustering, we defined a “core
Ts1Rhr set” of 50 genes (Supplementary Table 1A, Fig. 2a) that contained none of the
triplicated genes in Ts1Rhr cells but was highly enriched among Down syndrome-ALLs in
both the AIEOP dataset (Fig. 2c; FDR=0.001) and an independent validation dataset (ICH)
(Fig. 2c; FDR=0.001).
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tTo identify pathways perturbed by chr.21q22 triplication, we queried the Ts1Rhr gene set
against >3000 functionally defined gene sets in the MSigDB “c2” chemical and genetic
perturbations and “c6” oncogenic signatures repositories.22 Arranging the significant gene
sets in a network enrichment map23 defined 4 clusters (Fig. 2d). The most highly enriched
cluster consisted of polycomb repressor complex 2 (PRC2) targets and sites of tri-
methylated histone H3K27 (H3K27me3), the repressive mark added by PRC2, that were
defined across multiple lineages (Supplementary Table 1D–E). The additional clusters
consisted of gene sets that distinguish either stem cells from lineage-matched differentiated
cells, cancer cells from nonmalignant cells, or less differentiated from more differentiated
lymphoid cells (Supplementary Table 1D).
We next asked whether differential expression of PRC2/H3K27me3-classified genes would
distinguish Down syndrome-ALLs from other B-ALLs. A previous effort using genome-
wide expression in the AIEOP cohort failed to define a transcriptional signature specific to
Down syndrome-ALL19. Strikingly, expression of H3K27me3 targets defined in murine
embryonic fibroblasts24 distinguished Down syndrome-ALLs from non-Down syndrome-
ALLs (Fig. 2e). To validate these findings, we determined the 100 most differentially
expressed genes between Down syndrome-ALLs and non-Down syndrome-ALLs in the
AIEOP cohort across three different PRC2/H3K27me3 signatures (Supplementary Fig. S5a,
Supplementary Table 1F)24,25. All three signatures were significantly enriched (FDR≤0.001)
among Down syndrome-ALLs in the ICH validation cohort (Fig. 2f). In a third cohort of
non-Down syndrome-ALLs (AIEOP-2), leukemias with either polysomy 21 or iAMP(21)
clustered based on expression of PRC2 targets (Supplementary Fig. 5b, P=0.001 by Fisher’s
exact test), and the Ts1Rhr and H3K27me3 gene sets were enriched among cases with
polysomy 21 or iAMP(21) by GSEA (Supplementary Fig. 5c).
Genes from PRC2/H3K27me3 gene sets that distinguish Down syndrome-ALLs are
predominantly overexpressed in Down syndrome-ALL (Fig. 2e, Supplementary Fig. 5a),
suggesting that Down syndrome-ALL is associated with PRC2 target de-repression through
reduced H3K27me3. Histone H3 mass spectrometry confirmed a global reduction in
H3K27me3 peptides in passage 1 Ts1Rhr B cells compared to wild-type cells (Fig. 2g).
BCR-ABL B-ALLs from Ts1Rhr bone marrow also had reduced H3K27me3 by both mass
spectrometry and immunoblotting (Supplementary Fig. 5d–e). Thus, triplication of only 31
genes orthologous to chr.21q22 directly suppresses H3K27me3.
ChIP-seq of passage 1 Ts1Rhr B cells demonstrated a genome-wide reduction of
H3K27me3 at regions enriched for this mark in wild-type cells (Fig. 3a–b) that was
confirmed at multiple loci by ChIP-qPCR (Supplementary Fig. 6a). Within Ts1Rhr B cells,
H3K27me3 was found almost exclusively at regions enriched for H3K27me3 in wild-type
cells, suggesting little or no redistribution but rather a global reduction in H3K27me3
density (Supplementary Fig. 6b–d). As expected, reciprocal changes in activating
(H3K4me3, H3K27ac) and repressive (H3K27me3) marks were observed at promoters of
genes differentially expressed in Ts1Rhr B cells (Fig. 3c). However, genes “bivalently
marked” with both H3K27me3 and H3K4me3 in wild-type cells were highly enriched
among those overexpressed in Ts1Rhr B cells (Fig. 3d; P<0.0001).
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tBivalent marks may indicate genes that are modulated during lineage-specific
differentiation26. Thus, the global loss of H3K27me3 from chr.21q22 triplication may
selectively drive a progenitor B cell-specific developmental program. In support of this, the
Ts1Rhr and PRC2/H3K27me3 gene sets were highly enriched for predicted binding sites of
the master B cell transcription factors E2A/TCF3 and LEF1 (Supplementary Fig. 6e)24,25.
Genes within the Ts1Rhr gene set had increased proximal occupancy by E2A/TCF3
(Supplementary Fig. 6f), based on a previous dataset from wild-type and E2A-deficient
murine B cell progenitors24. In addition, the expression of genes within both the Ts1Rhr
gene set and the core Ts1Rhr set was preferentially increased in the presence of E2A/TCF3
(Supplementary Fig. 6g).
We hypothesized that pharmacologic restoration of H3K27me3 with GSK-J427, a selective
inhibitor of H3K27 demethylases, would block Ts1Rhr B cell repassaging. GSK-J4
increased H3K27me3 in Ts1Rhr B cells, decreased colony-forming activity, and blocked
indefinite repassaging (Fig. 3e,g). Previous studies demonstrated that 10µM GSK-J4 reduces
lipopolysaccharide-induced proinflammatory cytokine production by human primary
macrophages27. IC50 values for GSK-J4 across a panel of Down syndrome-ALLs ranged
from 1.4–2.5µM (Supplementary Fig. 6h). Treatment with GSK-12628, a selective inhibitor
of the PRC2 catalytic subunit EZH2, decreased H3K27me3 and was sufficient to confer
indefinite repassaging in wild-type B cells that was reversible upon drug withdrawal (Fig.
3f–h).
Among the 31 triplicated genes in Ts1Rhr cells is Hmgn1, which encodes a nucleosome
binding protein that modulates transcription and promotes chromatin decompaction3,5.
Modest increases in HMGN1 induce changes in histone H3 modifications and gene
expression4,29. Overexpression of HMGN1 in murine Ba/F3 B cells suppressed H3K27me3
in a dose-dependent fashion (Fig. 4a, Supplementary Fig. 7a). By RNA-seq, Hmgn1 was one
of only seven triplicated genes that maintained >70% of its passage 1 expression level at
passages 3 and 6 in all Ts1Rhr replicates (Supplementary Fig. 7b), suggesting it may be
necessary for serial repassaging. To address this, we transduced 5 shRNAs targeting each of
the 31 triplicated genes and controls individually into Ts1Rhr and wild-type passage 1 B
cells (Supplementary Fig. 7c). Transduced cells were pooled and serially passaged.
As expected, positive control shRNAs were equally depleted at later passages from Ts1Rhr
and wild-type backgrounds (Supplementary Fig. 7d, Supplementary Table 1G). Among
shRNAs against triplicated genes, two of the top four that most selectively depleted Ts1Rhr
B cells targeted Hmgn1 (Fig. 4b, Supplementary Table 1H). The remaining three shRNAs
targeting Hmgn1 also preferentially depleted Ts1Rhr B cells. By passage 6, all 5 shRNAs
against Hmgn1 were depleted >99% averaged across replicates. All five shRNAs also
reduced HMGN1 protein in Ba/F3 cells (Supplementary Fig. 7e).
Finally, we analyzed mice with transgenic overexpression of human HMGN1
(HMGN1_OE) at levels comparable to mouse HMGN1 (Supplementary Fig. 7f)30.
HMGN1_OE passage 1 B cells had a gene expression signature highly enriched for the
Ts1Rhr and core Ts1Rhr gene sets (Fig. 4c). Compared to control bone marrow,
HMGN1_OE bone marrow had reduced Hardy C cells in vivo (Supplementary Fig. 7g),
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tgenerated more B cell colonies in passages 1–4 in vitro (Fig. 4d), and resulted in greater
penetrance and shorter latency of BCR-ABL-induced B-ALL (Fig. 4e). Thus, HMGN1
overexpression recapitulates many transcriptional and phenotypic alterations observed from
triplication of all 31 Ts1Rhr genes.
In conclusion, we have shown that triplication of chr.21q22 genes confers cell autonomous
differentiation and transformation phenotypes in progenitor B cells. By first delineating
these biologic consequences of chr.21q22 triplication, we were able to more effectively
interrogate human B-ALL datasets and demonstrate that Down syndrome-ALLs are
distinguished by the overexpression of H3K27me3-marked genes. Our data also highlight
the therapeutic potential of H3K27 demethylase inhibitors for B-ALLs with extra copies of
chr.21q22. At the same time, EZH2 inhibitors may be useful for in vitro or in vivo expansion
of precursor B cells. Finally, we provide evidence that overexpression of HMGN1
suppresses global H3K27me3 and promotes B-ALL in vivo. Further studies are needed to
determine how HMGN1 modulates transcription at differentially expressed loci in cells with
polysomy 21 as well as the contributions from other triplicated chr.21q22 loci.
GEO Datasets
RNA-seq, ChIP-seq, and microarray expression data is available through GEO (GSE48555).
Online Methods
Mice
All animal experiments were performed with approval of the DFCI IACUC. All experiments
were performed in an FVB×C57BL/6 F1 background, unless otherwise specified. Ts1Rhr
(B6.129S6-Dp(16Cbr1-ORF9)1Rhr/J; #005838) and Ts65Dn (B6EiC3Sn.BLiA-
Ts(1716)65Dn/DnJ; #005252) mice were from Jackson Laboratories. HMGN1_OE mice
were previously described.30 Pax5+/− mice31 backcrossed to C57BL/6 were obtained from
M. Busslinger. Eµ-CRLF2 and Eµ-JAK2 R683G were generated by subcloing cDNAs
expressing human CRLF2 or mouse JAK2 R683G11,13 downstream of the immunoglobulin
heavy chain enhancer (Eµ) and generating transgenic founders in FVB fertilized eggs as
previously described.32. Controls for Ts1Rhr were wild-type littermates from crosses with
either C57BL/6 (Jackson; #000664) or FVB (Jackson; #001800) mice as indicated. Controls
for Ts65Dn were littermates from the colony (B6EiC3Sn.BLiAF1/J; Jackson #003647).
HMGN1_OE mice30 had been backcrossed >10 generations to C57BL/6.33 Controls for
HMGN1_OE were wild-type littermates after crossing with FVB mice. Donors for
competitive transplantation were congenic CD45.1+ B6.SJL-Ptprca Pepcb/BoyJ (Jackson;
stock #002014) crossed with FVB (CD45.1), C57BL/6×FVB F1 (CD45.1/2), or Ts1Rhr
(C57BL/6) crossed with FVB F1 (CD45.1/2). Recipients for competitive transplant, and
BCR/ABL and Ik6 bone marrow transplants were C57BL/6xFVB F1 female mice. No
randomization was performed for experiments involving mice or samples collected from
animals.
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tAntibodies
Western blotting antibodies were HMGN1 (Aviva Systems Biology, #ARP38532_P050),
HMGN1 (Abcam, #ab5212), mouse HMGN1 (affinity purified rabbit polyclonal)34,35,
H3K27me3 (Cell Signaling Technologies, #9733, rabbit polyclonal), total H3 (Cell
Signaling Technologies, #9715, rabbit polyclonal), and α-tubulin (Sigma, #T9026, mouse
monoclonal). Flow cytometry antibodies were B220-Pacific Blue (BD Pharmingen,
#558108, clone RA3-6B2), CD43-APC (BD, #560663, clone S7) or CD43-FITC (BD,
#561856, clone S7), CD24-PE-Cy7 (BD, #560536, clone M1/69), BP1-PE (eBiosciences,
12-5891, clone 6C3) or BP1-FITC (eBiosciences, 11-5891, clone 6C3), CD45.1-PE-Cy7
(eBiosciences, 25-0453, clone A20), and CD45.2-APC (eBiosciences, 17-0454, clone 104).
ChIP-seq antibodies were H3K27me3 (Cell Signaling Technologies, #9733), H3K4me3
(Abcam, #ab8580), and H3K27ac (Abcam, #ab4729).
Flow cytometry for bone marrow B cells
Whole bone marrow was harvested from femurs and tibias of 6–8-week-old mice. After red
blood cell lysis (Qiagen, #158904), B cell progenitors were stained using antibodies and
flow cytometry was performed as previously described.8 Analysis was performed on a BD
FACSCanto II.
Competitive bone marrow transplantation
Whole bone marrow was pooled from femurs and tibias of 8-week-old donor mice. Donor
cells were wild-type or Ts1Rhr CD45.1+/CD45.2+ C57BL/6xFVB F1 (test) and CD45.1+
B6.SJLxFVB F1 (competitor), and were mixed 1:1. Recipients were lethally irradiated (550
cGy x2, >4 h apart). B6.SJLxFVB F1 mice received 106 total cells via lateral tail vein
injection. Bone marrow was harvested 16 weeks after transplantation and analyzed by flow
cytometry.
Methylcellulose colony forming assays
Whole bone marrow was harvested from 6–8-week-old mice, and red blood cells were lysed.
Cells were plated in B cell (Methocult M3630, Stem Cell Technologies) or myeloid
(Methocult M3434) methylcelluose media in gridded 35 mm dishes. Myeloid colonies were
plated at 2×104 cells/ml per passage. B cell colonies were plated at 2×105 cells/ml in
passage 1, and at 5×104 cells/ml per subsequent passage. Colonies were counted at 7 days,
and colonies were then pooled and replated in the same manner.
BMT models
For BCR-ABL transplantations17, 105 transduced cells were transplanted with 106 wild-type
untransduced bone marrow cells for radioprotection. For generation of BCR-ABL B-ALLs
derived from Hardy B cells, 5×104 Hardy B cells from 6 week-old mice were sorted on a
BD FACSAria II SORP, spinoculation was performed as above, and 103 cells were
transplanted into lethally irradiated wild-type recipients with 106 bone marrow cells for
radioprotection. Dominant negative Ikaros experiments were performed similarly, except
106 cells spinfected with an MSCV retrovirus expressing GFP alone, or coexpressing GFP
and Ik614,36, were transplanted. Mice were followed daily for clinical signs of leukemia and
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twere sacrificed when moribund. Investigators were not blinded to the experimental groups.
10 mice were used per arm for 80% power to detect a 60% difference in survival at a
specific time point with alpha of 0.05. No animals were excluded from analysis.
Cell culture
Ba/F3 experiments were performed as previously described.13 shRNAs targeting Hmgn1 are
described below (competitive shRNA assay), and cDNA expressing HMGN1 was
previously described.29 One week after selection in puromycin, retroviral cDNA or lentiviral
shRNA-transduced cells were harvested for western blotting. hTERT-RPE1 cells were
cultured in DMEM/F-12. Mouse A9 cells containing a single human chromosome 21 tagged
with a neomycin resistance gene (a gift from Dr. M. Oshimura, Tottori University, Japan)
were cultured in DMEM. All medium was supplemented with 10% FBS, 100 IU/ml
penicillin, and 100 µg/ml streptomycin.
Immunoblotting and quantitation
Western blotting was performed as previously described.13 Image J (http://imagej.nih.gov/ij)
was used for quantitation of immunoblots, with band intensity normalized to total H3.
Microcell-mediated chromosome transfer (MMCT)
MMCT was performed as previously described37 with modifications. A9 cells were cultured
to ~70% confluence, and treated with 75 ng/ml colcemid for 48 hours. Cells were collected
and resuspended in 1:1 DMEM: Percoll (GE Healthcare Biosciences) with 10 µg/ml
Cytochalasin B (Sigma-Aldrich), and spun at 17,000 rpm for 75 minutes in a Beckman JA17
rotor. Supernatant was collected and filtered through 10 and 5 µm filters. Approximately
2×106 RPE1 cells were collected and mixed with filtered microcells, treated with 100 µg/ml
PHA-P (Sigma-Aldrich) for 30 minutes, and fused by PEG 1500 (Sigma-Aldrich) in
solution. Hybrid cells were plated and cultured for 48 hours, and selected with 500 µg/ml
Geneticin (Life Technologies) for 12–14 days. Standard G-band analysis was performed at
Karyologic, Inc. SNP array was performed at the DFCI microarray core, using the Human
Mapping 250k-Nsp platform. Fluorescent in situ hybridization was performed with the
Vysis LSI 21 SpectrumOrange probe (Abbott Molecular) according to the manufacturer’s
instructions.
DR-GFP and DR-GFP-CE reporter targeting
Generating and screening of targeted clones were performed as described38, with the
following modifications. 106 RPE1 cells with 2, 3, or 4 copies of chromosome 21 were
nucleofected with 2 µg pAAVS1-DRGFP or pAAVS1-DRGFPCE plasmid together with 2
µg pZFN-AAVS1, using program X-001 of the Amaxa nucleofector II (Lonza). Targeting of
individual clones was confirmed by PCR using the Accuprime GC-rich DNA polymerase
(Life Technologies). The presence of a single integrant was determined by qPCR (data not
shown).
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Assays for homologous recombination and imprecise non-homologous end-joining were
performed as previously described39 with the following modifications. Transfections were
performed with the Neon transfection system (Life Technologies) using 1600V, 20ms, and 1
pulse. 4×105 DR-GFP cells were transfected with 10 µg I-SceI expression vector (pCBASce)
or empty vector (pCAGGS) and plated in 6-well plates. pmCherry-C1 vector (Clonetech)
was transfected in parallel to confirm equal transfection efficiency. Cells were cultured for 7
days and analyzed by FACS using FACSCalibur (BD Biosciences) for homology-directed
repair. The remaining cells were used to extract genomic DNA. 1 µg DNA was digested
with 20U I-SceI (Roche) overnight, purified, and amplified with a two-step PCR protocol.
Accuprime GC-rich polymerase was used for the first step PCR (20 cycles), and Taq
polymerase (Qiagen) was used for the second step PCR (20 cycles). PCR products were
cloned with the TOPO TA cloning kit for sequencing (Life Technologies). For DR-GFP-CE,
pCAGGS-RAG1 and pCAGGS-RAG2 vectors were co-transfected. 1 µg genomic DNA was
digested with 10U MfeI and 10U NdeI (NEB) overnight to exclude templates that had not
been cleaved by RAG-1 and RAG-2 before PCR amplification. Primer sequences are
available in Supplementary Table 2.
Competitive shRNA assay in primary B cells
shRNAs targeting triplicated Ts1Rhr genes and controls were obtained from The RNAi
Consortium (http://www.broadinstitute.org/rnai/trc) as pLKO lentiviral supernatants40
(n=185, see Table S1 for clone ID# and target sequences). Wild-type or Ts1Rhr passage 1 B
cell colonies were collected and plated at 5×104 cells per well of a 96 well plate in 100 µl of
RPMI with 20% FBS, and 10 ng/mL each of murine IL7, stem cell factor, and FLT3 ligand
(all from R&D Systems), with 8 µg/ml polybrene. 10 µl of lentiviral supernatant was added
and the plate was centrifuged at 1000xg for 30 minutes, and then placed in a 37°C incubator
for 24 hours. Wells were pooled, 106 cells were saved for input shRNA analysis, and 2×106
cells were plated in 6 ml M3630 methylcellulose with 0.05 µg/ml puromycin in a 10 cm
non-tissue culture treated dish. At this density of plating, after 7 days of growth there were
at least 4×104 colonies per plate which would represent >200 colonies per individual shRNA
on average. After each passage, genomic DNA was harvested from 106 cells (Qiagen
QIAmp kit), and 2×106 cells were replated in the same manner. Repassaging continued until
cultures stopped forming new colonies (3–4 passages for wild-type) or until 6 passages were
completed. The entire assay was repeated in n=3 (wild-type) and n=4 (Ts1Rhr) independent
biological replicates.
The shRNA encoded in the genomic DNA was amplified using two rounds of PCR. Primary
PCR reactions were performed using up to 10 µg of genomic DNA in 100 µl reactions
consisting of 10 µl buffer, 8 µl dNTPs (2.5 mM each), 10 µl of 5 µM primary PCR primer
mix (see below) and 1.5 µl Takara exTaq. For the secondary PCR amplification the reaction
was performed as previously described 40 using modified forward primers, which
incorporated Illumina adapters and 6-nucleotide barcodes. Secondary PCR reactions were
pooled and run on a 2% agarose gel. The bands were normalized and pooled based on
relative intensity. Equal amount of sample was run on a 2% agarose gel and gel purified.
Samples were sequenced using a custom sequencing primer on an Illumina Hi-Seq and
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tquantitated as previously described.40 Primary, secondary, and sequencing primers are listed
in Supplementary Table 2.
RNA sequencing and data processing
Total RNA was harvested from B cell colonies (n=3 independent biologic replicates per
genotype per passage). RNA sequencing was performed at the DFCI Center for Cancer
Computational Biology. Quality control of total RNA was performed using the RNA Qubit
Assay (Invitrogen) and the Bioanalyzer RNA Nano 6000 Chip Kit (Agilent). At least 100 ng
of total RNA and a Bioanalyzer RNA Integrity Number of >7.0 were required. Library
construction was performed using TruSeq RNA Library Prep Kit (Illumina). Final library
quality control was performed using the DNA High Sensitivity Qubit Kit (Invitrogen), the
Bioanalyzer High Sensitivity Chip Kit (Agilent) and the 7900HT Fast qPCR machine
(Applied Biosystems). qPCR was performed using the Illumina Universal Library
Quantification Kit from KAPA Biosystems. RNASeq libraries were normalized to 2 nM,
pooled for multiplexing in equal volumes, and sequenced at 10 pM on the Illumina HiSeq
2000. Sequencing was performed as 2×50 paired-end reads using the 100 cycles per lane
Sanger/Illumina 1.9 deep sequencing protocol. The raw sequence data were subjected to
data quality control checks based on per base sequence quality scores, per sequence quality
scores, per sequence GC content, sequence length distribution, and overrepresented
sequences, which are implemented in the FastQC tool: (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads that passed quality control
filters were aligned against the mouse reference genome by using the ultra high-throughput
long read aligner Bowtie241 available through TopHat 2.0.7 (http://tophat.cbcb.umd.edu).42
Mapping results were further analyzed with TopHat to identify splice junctions between
exons. Genomic annotations in gene transfer format (GTF) were obtained from Ensembl
mouse genome GRCm38: (http://useast.ensembl.org/Mus_musculus/Info). Gene-level
expression measurements for 23,021 Ensembl mouse genes were reported in fragments per
kilobase per million reads (FPKM) by Cufflinks 2.0.0 (http://cufflinks.cbcb.umd.edu/).43 An
FPKM filtering cutoff of 0.1 in at least one sample was used to determine expressed
transcripts.
Differential analysis for RNA-Seq transcript expression
Differential analysis was performed by applying the EdgeR method44 implemented in
Bioconductor v2.11 (http://www.bioconductor.org/). EdgeR uses empirical Bayes estimation
and exact tests based on the negative binomial distribution model of the genome-scale count
data. EdgeR estimates the gene-wise dispersions by conditional maximum likelihood,
conditioning on the total count for that gene. The gene-wise dispersion is “normalized” by
shrinking towards a consensus value based on an empirical Bayes procedure.45 The
differential expression is estimated separately for each gene based on an exact test analogous
to Fisher’s exact test adopted for over-dispersed data.46
Gene expression profiling (GEP) and Gene Set Enrichment Analysis (GSEA)
The series matrix files for two DS-ALL datasets (AIEOP and ICH) and for were
downloaded from GEO (GSE17459)19, as were the Rag1−/− and E2A/Tcf3−/− B cell
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tprogenitors (GSE21978).47 RNA from HMGN1 transgenic (HMGN1_OE) or wild-type
littermate B cell colonies was processed and hybridized to Affymetrix Mouse Gene 2.0 ST
array at the DFCI Microarray Core per the manufacturer’s instructions. Raw probe-level
data from the AIEOP-2 non-DS-ALL cohort and the mouse HMGN1_OE GEP were
summarized using the Robust Multiarray Average (RMA)48 and Brainarray custom chip
identification files based on Entrez IDs (Version 17)49 using the ExpressionFileCreator
module in Gene Pattern.50 For GSEA the expression file was converted to human gene
orthologs using BioMart.51 GSEA of the Ts1Rhr, the core Ts1Rhr, and the PRC2 gene sets
was performed as previously described using GSEA v2.0.10 (http://www.broadinstitute.org/
gsea/).22 The Ts1Rhr gene set was tested for its enrichment in the c1 (positional), c2.cgp
(chemical and genetic perturbation), c3.tft (transcription factor targets), and c6 (oncogenic
signatures) gene sets deposited in the Molecular Signature Database MSigDB v3.1 (Broad
Institute; http://www.broadinstitute.org/gsea/msigdb). The analysis was performed by
applying the 2-tailed Fisher test method, as implemented in the Investigate_GeneSets
module at MSigDB. To define the Ts1Rhr B cell gene set, the top 150 most differentially
expressed protein coding genes with an adjusted p-value below 0.25 were selected.
Hierarchical clustering of this signature in DS-ALL vs non-DS-ALL revealed a subset of
genes most contributing to the distinguishing phenotype and this branch defined the “Core”
Ts1Rhr gene set. Full gene sets for BENPORATH_SUZ12_TARGETS,
MIKKELSEN_MEF_HCP_WITH_H3K27ME3, and
MIKKELSEN_MEF_NPC_WITH_H3K27ME3 were obtained from MSigDB v3.1. The 100
most differentially expressed genes between the DS-ALLs and the non-DS-ALLs were
determined using the MarkerSelectionModule in Gene Pattern. For E2A target gene
expression, we compared RAG1−/− proB cells to E2A−/− preproB cells to generate
probesets with >1.5-fold change and P<0.05 between conditions, exactly as had been done
by the authors.47 The Ts1Rhr and core gene sets were compared to all probesets for their
relative expression in E2A wild-type (RAG1−/− proB) vs E2A−/− cells.
Network enrichment mapping
The gene sets with significant enrichment in genes up-regulated in Ts1Rhr by GSEA were
selected based on the maximum cut-off value 0.05 for P-value and FDR, and visualized with
Enrichment Map software.23 This software organizes the significant gene sets into a
network, where nodes correspond to gene sets and the edges reflect significant overlap
between the nodes according to a Fisher’s test. The size of the nodes is proportional to the
number of genes in the gene set. The hubs correspond to collections of genes sets with
significant pair-wise overlap which have a unifying functional description according to GO
biological processes. The node color is associated to the functional description of the hub.
The clusters provided by the Enrichment Map are described in Table S1D.
Visualization of gene expression and mass spectrometry data
RNASeq-derived expression data from Ts1Rhr and wild-type B cells, B-ALL gene
expression data, and histone mass spectrometry data were visualized as heat maps using
GENE-E (Broad Institute; http://www.broadinstitute.org/cancer/software/GENE-E/).
Lane et al. Page 11
Nat Genet. Author manuscript; available in PMC 2014 December 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tColumn purification of mouse B-ALLs
For western blotting of mouse B-ALLs we enriched cryopreserved B-ALL splenocytes using
anti-CD19 antibody conjugated to magnetic microbeads (#130-052-201) and an MS MACS
column (#130-042-201), both from Miltenyi Biotec.
Histone mass spectrometry
Mass spectrometry for global Histone H3 post-translational modifications was performed as
previously described,52 using wild-type or Ts1Rhr passage 1 B cells and BCR-ABL B-
ALLs. H3K27 modifications are presented in conjunction with H3K36, as both are present
in the same measured peptides because of their close proximity. Significance calculated as
difference from log2 ratio of zero by t test.
Drug treatment
GSK-J4 (#M60063-2) and GSK-126 (#M60071-2) were purchased from Xcessbio. For
methylcellulose experiments, at each passage DMSO, GSK-J4, or GSK-126 were added to
cultures a final concentration of 1 µM. DS-ALLs (deidentified specimens obtained with
informed consent under DFCI IRB protocol 05-001) were treated in vitro in quadruplicate
with GSK-J4 at two-fold dilutions from 40 nM to 10 µM in RPMI with 20% calf serum
supplemented with 10 ng/mL IL3, IL7, SCF, FLT3 ligand, and 50 µM beta-mercaptoethanol.
After 3 days, viability was measured using CellTiter-Glo reagent and normalized to DMSO
control (Promega).
ChIP analyses
B cell colonies (>5,000 colonies per genotype) from 3 wild-type and 3 Ts1Rhr animals were
pooled after 7 days in methylcellulose culture. ChIP was performed as previously
described.53 Libraries for sequencing were prepared following the Illumina TruSeq DNA
Sample Preparation v2 kit protocol. After end-repair and A-tailing, immunoprecipitated
DNA (10–50 ng) or whole cell extract DNA (50 ng) was ligated to a 1:50 dilution of
Illumina Adaptor Oligo Mix assigning one of 24 unique indexes in the kit to each sample.
Following ligation, libraries were amplified by 18 cycles of PCR using the HiFi NGS
Library Amplification kit from KAPA Biosystems. Amplified libraries were then size-
selected using a 2% gel cassette in the Pippin Prep system from Sage Science set to capture
fragments between 200 and 400 bp. Libraries were quantified by qPCR using the KAPA
Biosystems Illumina Library Quantification kit according to kit protocols. Libraries with
distinct TruSeq indexes were multiplexed by mixing at equimolar ratios and running
together in a lane on the Illumina HiSeq 2000 for 40 bases in single read mode. Alignment
to mouse genome assembly NCBI37/mm9 and normalization were performed as previously
described.54 Regions of modified histones enriched in wild type and Ts1Rhr cells were
identified using MACS peak calling algorithm at a P-value of 1e-9.55 Location analysis of
ChIP-target enriched regions was performed using the CEAS software suite developed by
the Liu lab at DFCI.56 Promoters states were classified by the presence of H3K4me3,
H3K27me3, or both (bivalent) ChIP-seq enriched regions in the +/− 1kb region relative to
the transcriptional start site (TSS). ChIP-qPCR was performed on two independent sets of
pooled B cell colonies from 3 wild-type and 3 Ts1Rhr mice (primers available upon
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trequest). For analysis of upregulated genes in Ts1Rhr B cells, we excluded the 31 triplicated
genes in Ts1Rhr mice. Data are presented as boxplots designating median (black line), 1 SD
(box), and 2 SD (whiskers). E2A ChIP-Seq data from Rag1−/− proB cells were obtained
from GEO (GSE21978)47 and mapped to the genome as above. We defined regions of
enriched E2A genomic occupancy using the MACS algorithm as above. Genes were
considered associated with E2A if their gene body overlapped an E2A enriched region, or if
their TSS was within 50kb of an E2A enriched region, as was performed previously.57
Statistical analyses
Pairwise comparisons are represented as means +/− SEM by two-tailed Student t test, except
where otherwise specified. Categorical variables were compared using a Fisher’s exact test.
Kaplan-Meier survival curves were compared using the log-rank test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Segmental trisomy orthologous to human chr.21q22 promotes progenitor B cell
transformation
(a) Regions orthologous to human chromosome 21 that are triplicated in Ts1Rhr and
Ts65Dn mice or amplified in iAMP21 B-ALL. (b) Progenitor B cells (B220+CD43+) and
Hardy subfractions as percentages of bone marrow (BM) cells (n=5–7/group in 2
independent experiments). (c) Subfractions from mixed populations in recipient BM 16
weeks after competitive transplantation (n=5/group). (d) B cell colonies across 6 passages
(n=3 biological replicates/genotype representative of 3 independent experiments, mean
values shown, *P<0.05, **P<0.01), and bright field microscopy of 3 Ts1Rhr and 3 WT
passage 2 cultures (scale bar = 4 mm). (e) Myeloid colonies across 4 passages (n=3 mice per
genotype; NS, not significant). (f) Leukemia-free survival of recipient mice after
transplantation of Eµ-CRLF2 (C2)/Eµ-JAK2 R683G (J2)/Pax5+/− (P5), with or without
Ts1Rhr (Ts1) BM transduced with vector or dominant negative Ikaros (Ik6) (n=8–10 mice/
group). (g) Leukemia-free survival of recipient mice after transplantation of BM transduced
with BCR-ABL (n=10 mice/group).
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tFigure 2. Polysomy 21 B-ALL is associated with the overexpression of PRC2 targets
(a) Heat map of human genes orthologous to the 150 most upregulated genes from Ts1Rhr B
cells in primary human pediatric B-ALLs (“DS-ALL” represents Down syndrome-
associated ALL). Unsupervised hierarchical clustering by gene revealed the “core Ts1Rhr”
gene set (boxed). (b) GSEA plots for the full and core Ts1Rhr gene sets in the AIEOP data
set. ES, enrichment score. (c) GSEA plot of the core Ts1Rhr gene set in an independent ICH
validation cohort. (d) Network enrichment map of MSigDB gene sets enriched (FDR<0.05)
in the Ts1Rhr expression signature. (e) Unsupervised hierarchical clustering of H3K27me3-
marked genes from the MIKKELSEN_MEF_H3K27me3 gene set in the AIEOP pediatric B-
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tALL cohort (karyotype shown). (f) GSEA plots of the top 100 genes from three PRC2/
H3K27me3 gene sets as defined in the AIEOP patient cohort in the ICH validation cohort.
(g) Quantitative histone MS for H3K27-K36 peptides (*P<0.05, n=3 samples per group per
genotype).
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tFigure 3. Ts1Rhr B cells have reduced H3K27me3 that results in overexpression of bivalently
marked genes
(a) Gene tracks showing occupancy of histone marks at the Plod2 promoter (one of the 50
core Ts1Rhr genes) in reads per million per base pair (rpm/bp). (b) Levels of H3K27me3 in
Ts1Rhr and wild-type B cells at regions enriched for H3K27me3 in wild-type cells
(***P<1e-16). (c) Histone marks at the promoters of genes that are upregulated or
downregulated in Ts1Rhr vs. wild-type cells (**P< 1e-5). (d) Chromatin marks in wild-type
B cells present at promoters of all genes (left) or genes that are upregulated in Ts1Rhr B
cells (right, ***P<0.0001 compared to all genes by Chi-square with Yates’ correction). (e)
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tColony counts in the presence of DMSO or GSK-J4 (n=3–6 biological replicates per
genotype, *P<0.05 compared to DMSO for same genotype). (f) Colony counts in the
presence of GSK-126 or after withdrawal at passage 5 (*P<0.05 compared to GSK-126 for
same genotype, #P<0.05 compared to other genotype or no withdrawal). Arrow indicates
GSK-126 withdrawal. (g) Western blotting of passage 2 colonies after 14 total days in
culture with DMSO, 1 µM GSK-J4, or 1 µM GSK-126. (h) Western blotting of colonies one
passage (7 days) after continuation (+) or removal (−) of GSK-126.
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tFigure 4. HMGN1 overexpression decreases H3K27me3 and promotes transformed B cell
phenotypes
(a) Western blotting of Ba/F3 cells transduced with empty virus or murine HMGN1 (n=3
independent biological replicates). (b) Relative shRNA representation over passages 1–3.
Each line represents an individual shRNA (n=155 total). The five shRNAs targeting Hmgn1
are indicated. (c) GSEA plots for the full and core Ts1Rhr gene sets in HMGN1_OE
transgenic B cells. (d) B cell colonies during repassaging of WT and HMGN1_OE BM
(n=4–5 biological replicates per genotype from two independent experiments, *P<0.05). (e)
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tLeukemia-free survival of recipient mice after transplantation of wild-type or HMGN1_OE
bone marrow transduced with BCR-ABL (aggregate of three independent experiments
[Supplementary Fig. 8], n=20 [WT] or n=28 [HMGN1_OE] per group, curves compared by
log-rank test).
Lane et al. Page 23
Nat Genet. Author manuscript; available in PMC 2014 December 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t